Please login to the form below

Not currently logged in
Email:
Password:

Yuhan

This page shows the latest Yuhan news and features for those working in and with pharma, biotech and healthcare.

Janssen’s EGFR-targeting treatment regimen shows early benefit in lung cancer

Janssen’s EGFR-targeting treatment regimen shows early benefit in lung cancer

NSCLC. Janssen assessed the investigational drug in combination with EGFR tyrosine kinase inhibitor (TKI) lazertinib, which the company licensed from South Korean pharma firm Yuhan in 2018.

Latest news

More from news
Approximately 1 fully matching, plus 7 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Cuttsy + Cuttsy

How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...

Latest intelligence

Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...

Infographics